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yndrome But No Critical Epicardial Coronary Disease
TACTICS-TIMI-18 Substudy
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OBJECTIVES The purpose of this study is to determine whether there is clinical significance to elevated
troponin I in patients with suspected acute coronary syndromes (ACS) with non-critical
angiographic coronary stenosis.
BACKGROUND Elevation of troponin in patients admitted with ACS symptoms with non-critical coronary
artery disease (CAD) may result from coronary atherothrombosis not evident using standard
angiography or from other ischemic and non-ischemic causes that may confer increased risk
for future events.
METHODS Patients with ACS enrolled in the Treat Angina With Aggrastat and Determine Cost of
Therapy With Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction
(TACTICS-TIMI)-18 were included. Of 2,220 patients enrolled in the trial, 895 were
eligible. Patients were divided into four groups according to troponin status on admission and
presence of significant angiographic stenosis. Baseline brain natriuretic peptide (BNP) and
C-reactive protein (CRP) were obtained on all patients.
RESULTS The median troponin I levels were 0.71 ng/ml in patients with CAD compared with 0.02
ng/ml in patients without CAD (p  0.0001). Troponin-positive patients with or without
angiographic CAD had higher CRP and BNP levels compared with troponin-negative
patients (p  0.01 for both). The rates of death or reinfarction at six months were 0% in
troponin-negative patients with no CAD, 3.1% in troponin-positive patients with no CAD,
5.8% in troponin-negative patients with CAD, and 8.6% in troponin-positive patients with
CAD (p  0.012).
CONCLUSIONS Elevated troponin in ACS is associated with a higher risk for death or reinfarction, even
among patients who do not have significant angiographic CAD. The mechanisms
conferring this adverse prognosis merit further study. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.05619 –24) © 2005 by the American College of Cardiology Foundation
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Tardiac troponins are independent predictors of death or
einfarction in patients presenting with acute coronary
yndromes (ACS) (1–3). Moreover, troponin elevations in
CS have been associated with a higher incidence of
ultivessel disease, complex lesions, visible thrombus, and
mpaired myocardial perfusion (4–7).
The finding of elevated cardiac troponin in patients who
re subsequently found not to have non-critical epicardial
oronary artery disease (CAD) at angiography has been a
ource of confusion for clinicians, and led to concern over
false-positive” results with this biomarker (8). In this study,
e address for the first time this important clinical issue by
From the *Section of Cardiology, Baylor College of Medicine, Houston, Texas;
Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts;
Division of Cardiology, Baystate Medical Center, Springfield, Massachusetts; and
Merck and Co., West Point, Pennsylvania. For a complete listing of the TACTICS-
IMI-18 Investigators see reference 9.i
Manuscript received June 10, 2004; revised manuscript received September 15,
004, accepted September 19, 2004.valuating the outcome of patients with suspected ACS
ccording to the presence or absence of significant CAD on
ngiography and troponin status on admission.
ETHODS
tudy population. The data were drawn from an 895-
atient subset from the Treat Angina With Aggrastat and
etermine Cost of Therapy With Invasive or Conserva-
ive Strategy-Thrombolysis In Myocardial Infarction
TACTICS-TIMI)-18 trial who were randomized to the
nvasive strategy, had angiographic evaluation, and baseline
etermination of troponin I. The design of TACTICS-
IMI-18 has been previously described (9).
roponin testing. Cardiac troponin I (cTnI) was mea-
ured using the ACS:180 Chemiluminescensce troponin I
mmunoassay (Bayer Diagnostics, Tarrytown, New York).
his assay is an automated system using a two-site sandwichmmunoassay and direct chemoilluminescence technology.
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Troponin Positivity Without CAD in ACS January 4, 2005:19–24he manufacturer reports a lower limit of detection of 0.03
g/ml. The total imprecision determined in the core labo-
atory was characterized by a coefficient of variation of
0% at 0.4 ng/ml, 15% at 0.2 ng/ml, and 20% at 0.1
g/ml. On the basis of our prior work with this assay, the
hreshold used to define a positive cTnI test was 0.1
g/ml (10,11).
-type natriuretic peptide (BNP) and C-reactive protein
esting (CRP). Blood samples for BNP and CRP were
btained at enrollment in citrated tubes, and plasma was
solated within 60 min of acquisition. Aliquots for BNP
esting were shipped frozen to Biosite Inc. (San Diego,
alifornia), where they were thawed and analyzed using an
stablished immunoassay by personnel blinded to clinical
utcomes. The decision limit of 80 pg/ml was prespecified
ased on previous work with this assay (12); CRP levels
ere measured with the BN II Nephelometer (Dade-
ehring, Deerfield, Illinois), and a prespecified decision
imit of 15 mg/l was used (13).
ngiographic analysis. Only patients who were assigned
o the invasive arm with early coronary angiography (be-
ween 4 and 48 h after randomization) are included in this
nalysis. Patients were determined to have significant an-
iographic CAD if they had 50% stenosis in any of their
oronary arteries as assessed by the local study investigators.
here were five patients who had no stenoses 50% but
nderwent percutaneous coronary intervention during the
ndex hospitalization and were excluded from the present
nalysis. Investigators were not made aware of the patients’
roponin status.
tatistical analysis. Baseline demographics and electro-
ardiographic characteristics were compared between
roups using Pearsons’ chi-square test or Fisher exact test
if n 5) for categorical variables and Student t test or
nalysis of variance for continuous variables. Continuous
iomarker data are described as both median and mean
alues  SD and were compared using the nonparametric
ilcoxon rank-sum test (for two-way comparisons) or
ruskal-Wallis test (for four-way comparisons). A p
alue of 0.05 was considered statistically significant. All
nalyses were performed using STATA v8.0 (STATA
Abbreviations and Acronyms
ACS  acute coronary syndromes
BNP  B-type natriuretic peptide
CAD  coronary artery disease
CRP  C-reactive protein
cTnI  cardiac troponin I
TACTICS-TIMI  Treat Angina With Aggrastat and
Determine Cost of Therapy With
Invasive or Conservative Strategy-
Thrombolysis In Myocardial
Infarctionorp., College Station, Texas). 0ESULTS
aseline characteristics. Baseline clinical characteristics of
he study patients are shown in Table 1. Of the 895 patients
ho underwent angiography, 542 (61%) had elevated tro-
onin values, and 510 (94%) of the patients with elevated
roponin had evidence of significant angiographic CAD. Of
he remaining 353 patients with negative troponin, 278
79%) had evidence of significant CAD, whereas 75 (21%)
id not. As shown in Table 1, there were no differences in
moking status, congestive heart failure, or renal function
mong the four groups.
When comparing TnI-positive patients with angio-
raphic CAD to those without CAD, patients with elevated
roponin and CAD were more likely to have a history of
iabetes (p  0.034), hypertension (p  0.062), and
ypercholesterolemia (p  0.001). Similarly, TnI-positive
atients with CAD were more likely to be white (p 
.001) and have ST-segment depression on the initial
lectrocardiogram (p  0.009). The TnI-positive patients
ithout angiographic CAD were more likely to be females
han males (p  0.017).
roponin, BNP, and CRP. The median TnI level in
atients with CAD (n  788) was 0.71 ng/ml (interquartile
ange 0.02 to 5.7 ng/ml), compared with 0.02 ng/ml
interquartile range 0 to 0.24 ng/ml) in patients without
AD (n  107, p  0.0001).
Table 2 shows baseline BNP and CRP levels in the four
roups of patients. There were statistically significant dif-
erences in the median BNP and CRP levels between the
our groups, and in the percentage of patients with BNP
evels 80 pg/ml and CRP 1.5 mg/dl. Troponin-positive
atients with and without angiographic stenosis had similar
NP and CRP measurements. Both BNP and CRP levels
ere significantly higher in TnI-positive patients without
AD compared with TnI-negative patients without CAD
p  0.0001).
ix-month outcome by TnI status and CAD. As shown
n Table 3, the rate of death, reinfarction, or readmission for
CS was 15.5% for troponin-positive patients with CAD,
0.1% in troponin-negative patients with CAD, 6.3% in
roponin-positive patients without CAD, and 2.7% in
roponin-negative patients without CAD (p  0.001).
here was no significant difference in outcome between
roponin-positive patients with CAD compared with those
ithout CAD (p  0.20). We then tested for interaction
etween troponin level and CAD for the composite out-
ome at six months. There was no significant interaction
odds ratio 3.35, p  0.246). Figure 1 shows the Kaplan-
eier death or reinfarction-free survival curve at six months
or the four study groups. The rate of death or reinfarction
as 8.6% in patients with positive troponin and CAD
ompared with 5.8% in troponin-negative patients with
AD, 3.1% in troponin-positive patients without CAD,
nd 0% in troponin-negative patients without CAD (p 
.012). Troponin I positivity without CAD (odds ratio
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January 4, 2005:19–24 Troponin Positivity Without CAD in ACS5.7, 95% confidence interval 2.05 to 120.7, p  0.008),
roponin I positivity with CAD (odds ratio 11.6, 95%
onfidence interval 1.48 to 90.2, p  0.019), and gender
odds ratio 0.51, 95% confidence interval 0.32 to 0.81, p 
.005) were all independently associated with outcome on
ultivariate analysis for the triple composite end point. A
ultivariate analysis could not be done for death or rein-
arction alone because there were no events in the troponin-
egative no CAD group.
ix-month outcome by CAD and positive markers. The
ncidence of death, MI, or rehospitalization according to
he presence of positive markers or CAD is shown in
able 4. There was an incremental worsening in outcome
mong the four groups. The rate of death or reinfarction
as 0% in patients with all markers negative and no
AD, 2.1% in patients with any marker positive and no
able 1. Baseline Characteristics of Study Patients
TnI Negative, No CAD
(n  75)
TnI Positiv
(n 
ge, yrs (mean) 57.3  11.6 60.6 
ender (% male) 45.3 50
34/75 16
ace (% white) 69.3 53
52/75 17
iabetes (%) 16.0 15
12/75 5
ypercholesterolemia (%) 49.3 28
37/75 9
ypertension (%) 73.3 46
55/75 15
moker (%) 25.3 25
19/75 8
T deviation (%) 28.0 25
21/75 8
T elevation (%) 8.0 9
6/75 3
T depression (%) 20.0 15
15/75 5
x angina (%) 6.7 12
5/75 4
rior MI (%) 30.7 21
23/75 7
x CABG (%) 1.3 0
1/75 0
x PTCA (%) 40.0 18
20/75 6
x CHF (%) 2.7 9
2/75 3
VD (%) 4.0 3
3/75 1
x renal insufficiency (%) 2.7 3
2/75 1
CI during index
hospitalization (%)
0 0
0/75 0
ABG during index
hospitalization (%)
0 0
0/75 0
jection fraction (mean) 60.5  12.0 58.3 
reatinine (mean) 0.93  0.56 1.46 
ABG coronary artery bypass graft; CAD coronary artery disease; CHF conge
ntervention; PTCA  percutaneous transluminal; PVD  peripheral vascular diseaAD, 5.4% in patients with all markers negative and rAD, and 8.6% in patients with any marker positive
nd CAD (p  0.023).
ISCUSSION
e have previously demonstrated the strong prognostic
alue of cardiac troponin in patients with high clinical
uspicion for non–ST-segment elevation ACS (14). The
resent study demonstrates that, in the important group of
atients presenting with symptoms of ACS who were later
ound to not have angiographically significant CAD, the
resence of an elevated troponin is also associated with an
dverse prognosis. This finding challenges the idea that
hese are “false-positive” troponin results and that these
atients may be regarded as low-risk for subsequent cardio-
ascular events. Elevation of troponin in these patients may
CAD TnI Negative, CAD
(n  278)
TnI Positive, CAD
(n  510) p Value
62.3  10.4 62.5  11.0 0.002
61.5 70.2  0.001
171/278 358/510
80.9 79.6 0.001
225/278 406/510
23.4 33.7  0.001
65/278 172/510
74.1 60.0  0.001
206/278 306/510
67.3 63.3 0.044
187/278 323/510
27.3 31.2 0.514
76/278 159/509
26.3 47.3  0.001
73/278 241/510
7.6 13.9 0.040
21/278 71/510
20.5 38.8  0.001
57/278 198/510
20.5 11.2 0.001
57/278 57/510
53.2 34.1  0.001
148/278 174/510
29.1 17.5  0.001
81/278 89/510
44.6 20.6  0.001
124/278 105/510
8.3 6.5 0.336
23/278 33/510
11.2 6.9 0.060
31/278 35/510
1.4 2.2 0.830
4/278 11/510
43.2 50.2  0.001
120/278 256/510
12.6 28.8  0.001
35/278 247/510
54.2  12.7 51.6  12.5  0.001
1.01  0.25 1.01  0.30 0.0281
eart failure; Hx history; MImyocardial infarction; PCI percutaneous coronary
I  troponin I.e, No
32)
13.3
.0
/32
.1
/32
.6
/32
.1
/32
.9
/32
.0
/32
.0
/32
.4
/32
.6
/32
.5
/32
.9
/32
/32
.8
/32
.4
/32
.1
/32
.1
/32
/32
/32
9.5
2.31esult from coronary atherothrombosis not evident using
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Troponin Positivity Without CAD in ACS January 4, 2005:19–24tandard angiography or from other ischemic and non-
schemic mechanisms.
In the current study, 6% of patients who satisfied clinical
riteria for ACS and had elevated troponin early after
resentation were found not to have significant angio-
raphic coronary stenosis. Despite the absence of significant
oronary stenosis, this group of patients had a 3.1% inci-
ence of death, reinfarction, or rehospitalization for ACS at
ix months compared with 0% in troponin-negative patients
ithout angiographic CAD. The readmission rate at six
onths for troponin-positive patients without CAD was
.3% compared with 2.7% in troponin-negative patients
ithout CAD. Despite that this analysis is post hoc and
bservational in nature, multiple in number, it is
ypothesis-generating and not definitive.
Several mechanisms can be suggested to explain our
ndings. In this study, patients with significant CAD were
nly classified if they had angiographic evidence of 50%
iameter stenosis. It is likely that some patients who were
lassified to not have significant CAD had clinically impor-
ant coronary atherothrombosis (15). It is now recognized
hat angiography underestimates plaque burden. Other
atients may have presented late after the onset of symp-
oms, at a time where troponins were tracking down and the
egree of stenosis was less than expected. Finally, some
atients with ACS and positive troponin without significant
able 2. BNP and CRP by Presence of CAD on Catheterization
Negative, No CAD
on Cath
Ne
NP (pg/ml), median and IQ range 15 (0, 37)
(n  65)
NP 80 pg/ml (%) 6.2
4/65
RP (mg/l), median and IQ range 0.46
(0.21, 1.13)
(n  75)
(
RP 15 mg/l (%) 16.0
12/75
NP  B-type natriuretic peptide; CAD  coronary artery disease; Cath  corona
able 3. Six-Month Outcomes by Presence or Absence of CAD
Negative, No CAD
(n  75)
Posit
eath (%) 0
0/75
e-MI (%) 0
0/75
eath/re-MI (%) 0
0/75
ehospitalization for ACS (%) 2.7
2/75
eath, re-MI, rehospitalization 2.7
2/75CS  acute coronary syndromes; CAD  coronary artery disease; MI  myocardial infngiographic stenosis may have sustained myocardial isch-
mia secondary to coronary vasospasm.
In the current study, women comprised only 30% of the
roponin-positive patients with CAD compared with 50%
f the troponin-positive patients without CAD (p 0.017).
here has been much discussion in published reports about
oronary microvascular dysfunction and its prevalence in
omen without significant obstructive CAD (16–18). Sim-
larly, coronary erosions on mild coronary plaques have been
escribed to occur more often in women (19). This phe-
omenon may represent another potential explanation for
roponin release, increased CRP levels, and higher rate of
uture events without significant coronary stenosis.
Another novel finding in this study is that both BNP and
RP levels were increased in troponin-positive patients
ndependent of whether they had significant angiographic
isease or not. Several studies have shown that an elevated
RP or BNP in the setting of ACS is associated with worse
rognosis (12,20). It is possible that the mechanisms leading
o increased CRP and BNP in troponin-positive patients
ithout significant angiographic CAD differ from those for
atients with epicardial CAD, but still carry adverse conse-
uences. It is conceivable that etiologies such pulmonary
mbolism, left ventricular or diastolic dysfunction, myocar-
itis, pericarditis, or arrhythmias may have led into elevated
roponin in these patients with subsequent bad outcomes on
Troponin I Status on Admission
Troponin I
p Value
, CAD
ath
Positive, No CAD
on Cath
Positive, CAD
on Cath
39)
252)
19 (3, 57)
(n  29)
38 (8, 81)
(n  454)
0.0001
1 24.1 25.3  0.001
52 7/29 115/454
42 0.58 0.70 0.0001
0.97)
278)
(0.24, 1.59)
(n  32)
(0.28, 1,554)
(n  520)
4 25.0 25.5 0.063
78 8/32 130/510
iography; CRP  C-reactive protein; IQ  interquartile.
Troponin I Status
Troponin I
o CAD
32)
Negative, CAD
(n  278)
Positive, CAD
(n  510) p Value
2.2 3.5 0.288
2 6/278 18/510
4.3 5.9 0.064
2 12/278 30/510
5.8 8.6 0.012
2 16/278 44/510
15.8 10.4 0.002
2 44/278 53/510
20.1 15.5  0.001
2 56/278 79/510and
gative
on C
16 (3,
(n 
11.
28/2
0.
0.17,
(n 
18.
51/2and
ive, N
(n 
3.1
1/3
0
0/3
3.1
1/3
3.1
1/3
6.3
2/3arction.
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January 4, 2005:19–24 Troponin Positivity Without CAD in ACSollow-up. It is possible that some troponin-positive pa-
ients without angiographic CAD, in particular those with
ncreased BNP, may have suffered from other conditions
esulting in acute increases in ventricular wall stress, such as
on-ischemic cardiomyopathy, worsening heart failure, or
ulmonary embolism (21,22).
A graded relationship between baseline troponin levels in
atients with ACS and death upon intermediate follow-up has
een established (23). We have now shown that ACS patients
ith CAD have the greatest risk for adverse outcomes, whereas
atients with suspected ACS and elevated troponin but with-
ut CAD have an intermediate risk for recurrent cardiovascular
vents. As such, these findings underscore the notion that
levated levels of troponin in patients with suspected ACS
ithout significant CAD (sometimes labeled as “false-
ositives”) are the result of myocardial injury, and that these
atients are candidates for aggressive preventive therapies. The
able 4. Six-Month Outcomes by Presence or Absence of CAD
All Markers
Negative, No CAD
(n  53)
A
Posit
eath (%) 0
0/53
e-MI (%) 0
0/53
eath/Re-MI (%) 0
0/53
ehospitalization for ACS (%) 1.9
1/53
eath, re-MI, rehospitalization 1.9
1/53
igure 1. Kaplan-Meier curves for death/myocardial infarction (MI) at 1
roups: 1  troponin-negative/CAD-negative; 2  troponin-negative/CCS  acute coronary syndromes; BNP  B-natriuretic peptide; CAD  coronary arterynterventions offered must be guided by a clinical assessment of
he probable cause of myocardial injury.
tudy limitations. The analysis in the current study is
etrospective in nature, and the study population comes from a
linical trial dataset that focused on lower-risk patients and
xcluded patients with renal insufficiency and other high-risk
eatures. Troponin data were available at baseline only. The
umber of patients with positive troponin without CAD was
mall compared with the overall number of patients enrolled in
he study, and, therefore, the results should be interpreted with
aution. However, a similar analysis performed among patients
nrolled in the TIMI-IIIB study yielded similar outcomes.
nvestigator-determined coronary stenosis is subjective and not
ery reproducible. Angiographic CAD is not an accurate
ssessment of underlying atherosclerosis, especially if including
p to 50% stenosis. Our study was not designed to provide
nsight into the specific mechanisms resulting in myocardial
Marker Status (Troponin I, BNP, and CRP)
arker
o CAD
48)
All Marker
Negative, CAD
(n  185)
Any Marker
Positive, CAD
(n  590) p Value
1.6 3.7 0.328
8 3/185 22/590
4.9 5.8 0.098
8 9/185 34/590
5.4 8.6 0.023
8 10/185 51/590
18.4 10.5 0.001
8 34/185 62/590
22.2 15.9  0.001
8 41/185 94/590
ys by coronary artery disease (CAD) and troponin I status (p  0.029).
 troponin-positive/CAD-negative; 4  troponin-positive/CAD.and
ny M
ive, N
(n 
2.1
1/4
0
0/4
2.1
1/4
4.2
2/4
6.3
3/480 dadisease; CRP  C-reactive protein; MI  myocardial in fraction.
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Troponin Positivity Without CAD in ACS January 4, 2005:19–24njury in patients with suspected ACS and no critical epicardial
AD.
onclusions. Elevated levels of cardiac troponin in pa-
ients with suspected ACS are associated with a significantly
igher risk for death or reinfarction compared with
roponin-negative patients, even among those who do not
ave significant epicardial CAD on angiography. The
echanism of this adverse outcome requires further study.
eprint requests and correspondence: Dr. Nasser Lakkis, Ben
aub General Hospital, Baylor College of Medicine, Houston,
exas 77030. E-mail: nlakkis@bcm.tmc.edu.
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